Table 1.
Detailed information on SARS-CoV-2 serology assays.
| name | provider | platform | method | detection of Ab isotypes | antigen targeted | unit | cut-off for positivity | border-line | duration of test/batch | tests per h/run* |
sensitivity according to manufacturer | specificity according to manufacturer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Euroimmun | ||||||||||||
| Anti-SARS-CoV-2 ELISA (IgG) | EUROIMMUN AG, Lübeck, Germany | Euroimmun Analyzer I-2 P (EUROIMMUN AG, Lübeck, Germany) |
ELISA | IgG | S1-domain, spike protein (including the RBD) | Ratio | > 1.1 | 0.8 - 1.1 | 4.5 h | 180/run | 93.8 % (n = 16, ≥ 21 days since onset of symptoms) |
99.3 % (n = 150, German blood donors) |
| Diasorin | ||||||||||||
| LIAISON® SARS-CoV-2 S1/S2 IgG | DiaSorin S.p.A., Saluggia, Italy | LIAISON® XL Analyzer (DiaSorin S.p.A., Saluggia, Italy) | CLIA | IgG | S1 and S2 protein | AU/mL | > 15 | 12 - 15 | 35 min. | 180/h | 97.4 % (n = 39, > 15 days since onset of symptoms) |
98.5 % (n = 985, blood donors) |
| Roche | ||||||||||||
| Elecsys® Anti-SARS-CoV-2 | Roche Diagnostics Deutschland Gmbh, Mannheim, Germany | cobas e 411 (Roche Diagnostics Deutschland Gmbh, Mannheim, Germany) | ECLIA | total Ab | nucleocapsid protein | COI | > 1 | / | 18 min. | 75/h | 99.5 % (n = 185, ≥ 14 days since onset of symptoms) |
99.8 % (n = 4148, blood donors) |
| Wantai | ||||||||||||
| WANTAI SARS-CoV-2 Ab ELISA | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Beijing, China | Euroimmun Analyzer I-2 P (EUROIMMUN AG, Lübeck, Germany) |
ELISA | total Ab | recombinant SARS-CoV-2 antigen (RBD) | A/C.O. | > 1 | 0.9 - 1.1 | 4 h | 180/run | 94.5 % (n = 310, 1−39 days since onset of symptoms) |
100 % (n = 333, healthy individuals) |
| Siemens | ||||||||||||
| Atellica® IM SARS-CoV-2 Total (COV2T) | Siemens Healthcare Gmbh, Erlangen, Germany | Atellica® IM Analyzer (Siemens Healthcare Gmbh, Erlangen, Germany) | CLIA | total Ab | spike protein | Index | > 1 | / | 10 min. | 440/h | 100 % (n = 42, ≥14 days since onset of symptoms) | 99.8 % (n = 993, healthy individuals) |
* on the respective platform.
Abbreviations: Ab, antibody; A/C.0., absorbance/cut-off; AU/mL, arbitrary units/mL; CLIA, chemiluminescence immunoassay; COI, Cut-off index (sample signal/cut-off); ECLIA, electroluminescence assays; ELISA, enzyme-linked immunosorbent assay; h, hours; IgG, immunoglobin G, Ratio, ratio (extinction sample/extinction calibrators); max., maximum; min., minutes; n/a, data not available; No., number.